Neurogene (NASDAQ:NGNE) may be facing weaker earnings than anticipated, according to a report on Yahoo Finance. Investors should take note of this potential downside as they assess their investment in the company. It is important to stay informed and keep a close eye on Neurogene’s performance in the coming months.
Subscribe
Login
0 Comments